As an alternative to the $600 million non-core intellectual asset transaction it had agreed to with Catapult IP Innovations, BlackBerry Ltd. (NYSE: BB) said it is looking into other possibilities.
Catapult, the U.S.-based particular purpose vehicle that had agreed to buy the heritage patents. It said on Wednesday that it no longer had exclusivity with Blackberry, a Canadian cybersecurity business. However, the deal was scheduled to be finalized in 2023.
According to BlackBerry, Catapult is still in the process of raising money. With so much time since the transaction was initially agreed upon, BlackBerry says it is considering alternative possibilities.
On January 31, BlackBerry announced plans to sell most of its patents, mainly pertaining to mobile devices and messaging.
After a Panel Considers Covid Research, Adamis Pharmaceuticals is on the rise.
To celebrate the news that the Covid-19 study should be continued, shares of Adamis Pharmaceuticals Corp. (NASDAQ: ADMP) shot up by 5% in premarket trading.
According to the biopharmaceutical business, interim clinical and safety data have been examined and authorized for the Phase 2/3 clinical research exploring the use of Tempol to treat Covid-19. This trial is presently being conducted by a Data Safety Monitoring Board.
Scientists at Stanford University cooperated with Adamis to undertake in-vitro anti-cytokine research, which discovered Tempol to be active.
Animals subjected to a SARS-COV2 challenge model had less inflammation in their lungs after receiving Tempol, according to the company.
The post Blackberry Considers Alternative To Selling Catapults As Continuation Of Covid-19 Means More Room For Adamis Pharmaceuticals Corp. appeared first on Best Stocks.
